Dashboard
Manage Tickers

REGN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

governor-hochul-announces-regeneron-to-invest-more-than-2-billion-into-saratoga-county-facility-creating-1000-new-jobs
Governor Hochul Announces Regeneron to Inv...
11/13/2025 19:47:56

https://www.governor.ny.gov/news/governor-hochul-announces-regeneron-invest-more-2-billion-saratoga-county-facility-creating

wall-street-falls-on-us-government-reopening-day-bitcoin-slides-to-100000-whats-moving-markets-thursday
Wall Street Falls On US Government Reopeni...
11/13/2025 17:37:18

Risk sentiment deteriorated sharply on Thursday despite federal agencies reopening after the longest government shutdown in U.S...

crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial
CRISPR Therapeutics' Investigational Gene ...
11/11/2025 14:50:51

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its...

reported-saturday-regeneron-reports-robust-anti-clotting-effects-for-regn7508cat-and-regn9933a2-in-total-knee-replacement-patients-with-no-clinically-relevant-bleeding
Reported Saturday, Regeneron Reports Robus...
11/10/2025 09:13:33

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron's two mechanistically-distinct antibodies agains...

ubs-maintains-neutral-on-regeneron-pharmaceuticals-raises-price-target-to-660
UBS Maintains Neutral on Regeneron Pharmac...
11/07/2025 17:52:48

UBS analyst Trung Huynh maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $5...

regeneron-pharmaceuticals-trial-data-from-liberty-afrs-aims-phase-3-study-shows-dupixent-improves-signs-symptoms-of-allergic-fungal-rhinosinusitis-reduces-sinus-opacification-nasal-congestion-and-nasal-polyps
Regeneron Pharmaceuticals Trial Data From ...
11/07/2025 13:11:51

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive results from the pivotal...

regeneron-presents-results-showing-liberty-afrs-aims-phase-3-trial-of-dupixent-met-all-primary-and-secondary-endpoints
Regeneron PResents Results Showing LIBERTY...
11/07/2025 13:08:00

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
11/06/2025 15:30:59

looking-into-regeneron-pharmaceuticals-incs-recent-short-interest
Looking Into Regeneron Pharmaceuticals Inc...
11/04/2025 19:00:36

michael-burry-is-super-bearish-on-palantir--with-5-million-puts
Michael Burry Is Super-Bearish On Palantir...
11/03/2025 23:17:30

Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, am...

rbc-capital-maintains-sector-perform-on-regeneron-pharmaceuticals-raises-price-target-to-708
RBC Capital Maintains Sector Perform on Re...
10/29/2025 16:56:39

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the pr...

wells-fargo-maintains-equal-weight-on-regeneron-pharmaceuticals-raises-price-target-to-615
Wells Fargo Maintains Equal-Weight on Rege...
10/29/2025 14:16:08

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price ...

cantor-fitzgerald-maintains-overweight-on-regeneron-pharmaceuticals-raises-price-target-to-740
Cantor Fitzgerald Maintains Overweight on ...
10/29/2025 13:50:33

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the pr...

guggenheim-maintains-buy-on-regeneron-pharmaceuticals-raises-price-target-to-865
Guggenheim Maintains Buy on Regeneron Phar...
10/29/2025 12:46:20

Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target fro...

b-of-a-securities-maintains-underperform-on-regeneron-pharmaceuticals-raises-price-target-to-627
B of A Securities Maintains Underperform o...
10/29/2025 12:06:41

B of A Securities analyst Tim Anderson maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Underperform and raises the ...

Core News & Articles
ModeX Therapeutics Enters License, Collabo...
10/29/2025 12:02:41

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collabora...

nasdaq-100-hits-26000-gold-falls-below-4000-whats-moving-markets-tuesday
Nasdaq 100 Hits 26,000, Gold Falls Below $...
10/28/2025 17:23:51

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech...

wayfair-qorvo-celestica-united-parcel-service-regeneron-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday
Wayfair, Qorvo, Celestica, United Parcel S...
10/28/2025 14:14:02

regenerons-q3-earnings-outperform-expectations-with-dupixent-strength-balancing-eylea-weakness
Regeneron's Q3 Earnings Outperform Expecta...
10/28/2025 13:13:27

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION